The present invention concerns the biotechnology sector and more specificallyhuman healthcare. In particular, the present invention describes a vaccinecomposition for therapeutic use thereof on cancer patients. The vaccine compositiondescribed in the present invention has as active principle a chemical conjugateof human recombining Epidermic Growth Factor (hrEGF) and recombining proteinP64k. In addition, specific conditions are described for performing a conjugationreaction which produces said chemical conjugate in a controlled and reproduciblemanner. In another embodiment the present invention concerns a method for purificationof the chemical conjugate which not only provides greater purity for the therapeuticcomposition, but surprisingly increases the immunogenic activity, causingsignificant increases in the anti-EGF antibody titres in humans. In additionthe present invention provides the methodology for producing a vaccine preparationwith more than one type of dose presentation (total milligrams of EGF-P64k conjugates/vial).This versatility in the presentation of the vaccine preparation enables theimmunization dose per patient to be increased, but without involving an increasein immunization frequency and/or the number of immunization sites. Finally,the present invention involves a healthcare method for producing the vaccinefor cancer therapy, administered by parenteral means.
